Entries |
Document | Title | Date |
20080200441 | ESTROGEN RECEPTOR MODULATORS ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE - Selective estrogen receptor modulators, as well their related pharmaceutical compositions and methods of use, are provided herein. These estrogen receptor modulators include compounds that primarily exhibit estrogen receptor antagonist activity or primarily exhibit selective estrogen receptor antagonist and agonist activity, i.e., SERM activity, in specific tissue types. Particular embodiments provide compounds that behave as NeuroSERMs promoting neurotrophism and neuroprotection in brain tissue. These NeuroSERMs represent a subset of the modulators compounds provided herein that can cross the blood-brain-barrier and exert estrogen receptor agonist-like effects in the brain. The compounds should be useful for treating a variety of diseases, particularly estrogen receptor-mediated diseases and disorders, such as osteoporosis, breast and endometrial cancers, atherosclerosis and Alzheimer's disease. | 08-21-2008 |
20080207579 | Uses of tetrahydrobiopterin and derivatives thereof - The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor. | 08-28-2008 |
20080207580 | METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent. | 08-28-2008 |
20080214515 | Process for Preparing 3a(Beta)-7a(Beta)-Dihydroxy-6a(Beta)-Alkyl-5Beta-Cholanic Acid - Process for preparing 3α-7α(β)-di-hydroxy-6α(β)-alkyl-5β-cholanic acid (I) in which R is a linear or branched C | 09-04-2008 |
20080214516 | METHODS AND COMPOSITIONS FOR INHIBITING TUMOR GROWTH - The present invention relates to novel betulinic acid derivatives with increased activity for the treatment of carcinomas and HIV diseases, a method for preparing such novel betulinic acid derivatives as well as their use as pharmaceuticals. | 09-04-2008 |
20080214517 | Modulation of the Expression of Estrogen Receptors for the Prevention or Treatment of Heart Disease - The present invention relates to the upregulation of estrogen receptors (ER) alpha (ERα) and/or beta (ERβ) in endothelial cells and/or smooth muscle cells to prevent or treat heart disease. The upregulation is achieved through the use of recombinant DNA technology and, depending on therapeutic needs, may be performed with a simultaneous or subsquent downregulation, as with antisense technology. Oligonucleotides coding for ERα and/or ERβ are introduced into the targeted cells through the use of adenoviruses, for example. With an increase in receptors, the cells should be more responsive to such agonists as 17-beta-estradiol (17βE) and related compounds (genistein, estradiol derivatives . . . ) to improve plaque stabilization, vascular healing and endothelial recovery after vascular injury. Such oligonucleotides may be used to modulate the beneficial effects mediated by the ER on vascular healing, for example, restenosis or plaque stabilisation, in mammals. They may further be used in the prevention or treatment of a disease or disorder characterised by atherosclerosis, plaque vulnerability or destabilisation or pathological plaque rupture or erosion including spontaneous or induced injury. | 09-04-2008 |
20080221074 | Drug Screen and Treatment Method - The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one. | 09-11-2008 |
20080221075 | Therapeutic Uses For Aminosterol Compounds - A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. | 09-11-2008 |
20080234245 | Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma - Compositions of angiostatic agents for treating choroidal neovascularization resulting from ocular surgery or from trauma to ocular tissue and methods for their use are disclosed. | 09-25-2008 |
20080255077 | Drug and Food or Drink for Improving Pancreatic Functions - Compounds such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol which have an activity for improving pancreatic function are used as an active ingredient of a pancreas function improving drug and food or drink. | 10-16-2008 |
20080255078 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators - Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation. | 10-16-2008 |
20080269183 | Novel Therapy for Treatment of Chronic Degenerative Brain Diseases and Nervous System Injury - In one aspect the present invention provides neuroactive steroids for use in the treatment of nervous system disorders, degenerative brain diseases and congenital storage diseases. In a second aspect the invention provides neuroactive steroids in combination with a Liver X Receptor (LXR) ligand to effect treatment of a nervous system condition. | 10-30-2008 |
20080275016 | FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 11-06-2008 |
20080275017 | AROMATIC SULFENATES FOR TYPE I PHOTOTHERAPY - Novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon photofragmentation of the sulfenate moiety, with the tissue of interest. | 11-06-2008 |
20080280865 | WATER-IN-OIL TYPE EMULSIFIED COMPOSITION - Water-in-oil type emulsified compositions with a high silicone oil content which are excellent in emulsification stability and whose sticky feeling has been improved may be obtained by incorporating a specific (A) N-long chain acyl neutral amino acid ester, (B) a silicone oil, and (C) water therein. | 11-13-2008 |
20080318916 | Novel alpha glucosidase inhibitors from lichens - This invention is directed to a novel method for the inhibition of α-glucosidase enzyme and thus treating diabetes, viral infections, fungal infections, autoimmune function disorders and obesity using compounds derived as lichen metabolites; more specifically, this includes the therapeutic applications of methylorsellinate (2,4-dihydroxy-6-methylbenzoate, Compound I), methyl-β-orinolcarboxylate (2,4-dihydroxy-3,6-dimethylbenzoate, Compound II) and zeorin (6,22-hopanediol, Compound III). | 12-25-2008 |
20090012053 | Use of LXR agonists for the treatment of osteoarthritis - Disclosed herein are methods of preventing and treating osteoarthritis through the use of LXR agonists. | 01-08-2009 |
20090023698 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID - The present invention provides a method for preparing a compound of formula (I), the method comprising contacting a compound of formula (II) with an effective amount of a compound of formula (III) or (IV). The present invention also provides a method for preparing a compound of formula (VI), the method comprising contacting a compound of formula (II) with an effective amount of one or more of 2,2-dimethylsuccinic acid, 2,2 dimethylbutanedioyl dichloride, 2,2-dimethylbutanedioyl dibromide, and 2,2 dimethylsuccinic anhydride. The present invention also provides a compound obtained from the method of the present invention. | 01-22-2009 |
20090023699 | Method For Obtaining a Natural Mixture of Conjugated Equine Estrogens Depleted in Non-Conjugated Lipophilic Compounds - A method for obtaining an extract containing the natural mixture of conjugated equine estrogens by liquid-liquid extraction of the mixture of conjugated equine estrogens, wherein the mixture obtained is depleted in non-conjugated lipophilic compounds selected from the group consisting of non-conjugated flavonoids, non-conjugated isoflavonoids, non-conjugated norisoprenoids, non-conjugated steroids, in particular androstane and pregnane steroids, and comparable non-conjugated compounds. | 01-22-2009 |
20090036415 | Identification and treatment of estrogen responsive prostate tumors - The present invention is directed to specific chromosomal rearrangements that are associated with prostate tumors that respond to compounds acting at estrogen receptors. Patients having the TMPRSS2-ERG fusion, may be treated with agonists of the estrogen beta receptor or antagonists of the estrogen alpha receptor. | 02-05-2009 |
20090054389 | Topical Composition Comprising an Antibacterial Substance - A pharmaceutical composition for topical application comprises a fusidic acid derivative of general formula I as disclosed herein and one or more monoglycerides of a fatty acid. The composition may be used in the treatment of a disease or condition of the skin or mucosa, in particular skin infections. | 02-26-2009 |
20090075963 | TRANSDERMAL HORMONE SPRAY - The present invention provides a transdermal spray drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention. | 03-19-2009 |
20090075964 | FRAGRANCE COMPOSITIONS AND OTHER COMPOSITIONS WHICH CONTAIN NATURALLY OCCURRING SUBSTANCES FOUND IN CORALS - This invention is generally related to the fields of fragrance compositions, personal care products, and home consumer products. This invention also relates to 20-pregnenes, in particular those found naturally occurring in corals and which affect mood in humans, to the incorporation of these 20-pregnene compounds into various compositions, and to methods of affecting the mood of individuals using such compounds. | 03-19-2009 |
20090082322 | Gender Differences in Experimental Aortic Aneurysm Formation - The present invention generally relates to the relevance of gender differences on abdominal aortic aneurysm (AAA) formation and to methods of inhibiting, preventing, and/or treating AAA formation by administering estrogen, and estrogen derivative, and/or estrogen receptor agonist, to an organism in need thereof. | 03-26-2009 |
20090082323 | DEUTERIUM-ENRICHED FULVESTRANT - The present application describes deuterium-enriched fulvestrant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090093450 | AGENT FOR INHIBITING VISCERAL FAT ACCUMULATION - To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant, or a fraction thereof containing the compound is used as an active ingredient. | 04-09-2009 |
20090099149 | BIOADHESIVE FILM - Bioadhesive films for delivery of active agent to the mucosa are disclosed. Particularly, bioadhesive films for treating the vaginal mucosa are disclosed. | 04-16-2009 |
20090105203 | COMPOUNDS FOR TREATING VIRAL INFECTIONS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. | 04-23-2009 |
20090105204 | Therapeutic Uses for Aminosterol Compounds - A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. | 04-23-2009 |
20090105205 | METHODS OF TREATING DISEASE STATES USING ANTIANGIOGENIC AGENTS - Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: | 04-23-2009 |
20090131388 | Agent for Improving Insulin Resistance - To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance or ameliorate the pathosis, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant or, a fraction thereof containing the compound as an active ingredient. | 05-21-2009 |
20090131389 | Preparation of a Crystalline Antibiotic Substance - The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections. | 05-21-2009 |
20090137544 | Formation and rejuvenation of organs and alcohol damaged organ regeneration through stem cell nutrients - Mechanisms nourish stem cells for organ regeneration and prevent alcohol related diseases such as Fetal Alcohol Syndrome (FAS) and Liver Sclerosis. These stem cell nutrients have been found to positively affect the skin, liver, brain neurons, pancreas, and the GI tract. Cholesterol supplementation prevents fetal alcohol spectrum defects (FASD) in alcohol-exposed zebra fish embryos. Using the zebra fish model, alcohol was found to interfere with embryonic development by disrupting cholesterol-dependent activation of a critical signaling molecule, sonic hedgehog (Shh). Cholesterol supplementation of the alcohol-exposed embryos restored the functionality of the molecular pathway and prevented development of FASD-like defects. Novel biomarkers were identified for diagnosing alcohol related diseases by lipid chemical analysis and Raman Spectroscope. | 05-28-2009 |
20090143349 | STEROID TETROL SOLID STATE FORMS - The invention relates to solid state forms of androst-5-ene-3β,7β,16α,17β-triol, formulations containing or prepared from such solid state forms and use of such materials for modulating acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity such as arthritis, multiple sclerosis, ulcerative colitis or Type 1 diabetes. The formulations can also be used to prevent, treat or slow the progression of conditions related to metabolic disorders such as Type 2 diabetes. | 06-04-2009 |
20090143350 | Anxiolytic Marcgraviaceae Compositions Containing Betulinic Acid, Betulinic Acid Derivatives, and Methods - Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject. | 06-04-2009 |
20090163459 | Use of 24-nor-UDCA - The present invention relates to the use of nor-ursodeoxycholic acid for the manufacture of a drug for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases. | 06-25-2009 |
20090163460 | DIAGNOSTICS AND THERAPEUTICS FOR EARLY-ONSET MENOPAUSE - A method of predicting whether a subject is predisposed to developing early-onset menopause is provided. The method involves genotyping a patient at the IL-1 gene loci. | 06-25-2009 |
20090197851 | THERAPY AND USE OF COMPOUNDS IN THERAPY - A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. | 08-06-2009 |
20090239837 | CHOLESTEROL-PRODUCING YEAST STRAINS AND USES THEREOF - The invention concerns the production of cholesterol in organisms of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol. | 09-24-2009 |
20090247497 | FORMULATION AND USE OF ERGOSTA-7,22-DIEN-3BETA-OL - An isolated and purified form of ergosta-7,22-dien-3β-ol and its use as a marker for identifying | 10-01-2009 |
20090258850 | STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS - The invention relates to pharmaceutically acceptable formulations comprising an active pharmaceutical ingredient such as androst-5-ene-3β,17β-diol, androst-5-ene-3β,7β,17β-triol or derivatives of either of these compounds and an air oxidizable excipient that have been stabilized with respect to efficacy. Use of the efficacy-stabilized formulations to treat a number of conditions or symptoms thereof, such as a symptom associated with exposure to radiation is described. | 10-15-2009 |
20090275544 | Method and kit for reducing the symptoms of peripheral vascular disease - A method for reducing the symptoms of peripheral vascular disease and for improving peripheral circulation wherein a progestin is administered to a subject in need thereof. | 11-05-2009 |
20090275545 | Medicinal targeted local lipolysis - Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue. | 11-05-2009 |
20090281070 | Method for Preparing a Solid Pharmaceutical Composition with Sustained and Controlled Release by High Pressure Treatment - The invention concerns a method for preparing a unit-dose of a solid pharmaceutical composition with prolonged and controlled release by high pressure treatment of a solid composition comprising at least one active principle and at least one polymer. The invention also concerns the resulting solid pharmaceutical compositions. | 11-12-2009 |
20090281071 | THERAPEUTIC AGENT FOR HYPERTENSION - The present invention provides a novel hypertension therapeutic agent. | 11-12-2009 |
20090291931 | COMPOSITIONS WITH ENHANCED ELASTICIZING ACTIVITY - Compositions for improving the elasticity of the vagina and of the perineum during the last trimester of pregnancy, include combining a thiolated compound or mixture thereof with an ester of organic acid or mixture thereof. The compositions according to the present invention improve the elastic properties of the vaginal and/or perineal tissues in terms both of increased extensibility and faster elastic recovery. The compositions according to the present invention may decrease risk of trauma of perineal tissues during delivery, as well as risk of rectal or bladder incontinence as a post-partum short/medium/long term complication. | 11-26-2009 |
20090291932 | PHARMACEUTICAL SOLID STATE FORMS - The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions. | 11-26-2009 |
20090291933 | SOLID STATE FORMS OF A PHARMACEUTICAL - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 11-26-2009 |
20090306032 | Use of solid lipid nanoparticles Comprising Cholesteryl Propionate and/or Cholesteryl Butyrate - The present invention refers to the use of solid lipid nanoparticles (SLN) obtained from warm microemulsions, containing cholesteryl propionate and/or cholesteryl butyrate, for preparation of a medicament for the prevention and treatment of vascular or inflammatory pathologies. | 12-10-2009 |
20090312297 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS - The invention provides compounds and pharmaceutical compositions that can be used to treat or prevent atherosclerosis, stroke, and other ischemic vascular diseases, dyslipidemia and hypercholestcrolemia and prevent complications of these conditions. Agents in accordance with the invention include; tauroursodeoxycholic acid (TUDCA), and analogs and derivatives thereof; 4-phenyl butyric acid (PBA), and analogs and derivatives thereof; and trimethyl N-oxide (TMAO), and analogs and derivatives thereof. | 12-17-2009 |
20090312298 | Methods and Compositions Related to GABA Receptor Subunits - Disclosed are compositions and methods related to GABA | 12-17-2009 |
20090312299 | Isolated Isomers of Norelgestromin and Methods of Making and Using the Same - The invention is directed to a process of preparing substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention include a composition comprising substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime or substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer, and methods of treatment using said compositions. | 12-17-2009 |
20090318400 | METHOD FOR INHIBITING TUMOR GROWTH WITH DEHYDROSULPHURENIC ACID EXTRACTED FROM ANTRODIA CINNAMOMEA - The present invention relates to a method for inhibiting tumor growth, in particular to the method using dehydrosulphurenic acid to inhibit the growth of leukemia cell or pancreatic cancer cell by a compound extracted and purified from | 12-24-2009 |
20090318401 | USE OF ESTRIOL IN LOW DOSES - The invention relates to the use of low doses of estriol by vaginal route for treatment and/or prevention of urogenital atrophy due to estrogen deficit in women. | 12-24-2009 |
20100016269 | COMPOSITION OF PLANT STEROL AND PHOSPHATIDYLCHOLINE AND METHOD FOR PRODUCING THE SAME - The present invention is intended to discover a composition that contains a large amount of a plant sterol completely insoluble in water and exhibiting poor solubility in oil because of its extremely high crystallinity. Such composition can be easily dispersed in water, and to produce the composition. It has been discovered that a composition obtained by adding and dissolving a small amount of phosphatidylcholine in a plant sterol that is hardly soluble in water or in oil results in such composition easily dispersible in water. | 01-21-2010 |
20100022495 | MODULATING ENDOPLASMIC RETICULUM STRESS IN THE TREATMENT OF TUBEROUS SCLEROSIS - Endoplasmic reticulum stress has been found to be associated with the genetic disease tuberous sclerosis. Tuberous sclerosis is cause by defects in the two genes, TSC1 and TSC2. Agents that modulate ER stress may be used to treat tuberous sclerosis and other hamartomatous diseases. In particular, 4-phenyl butyric acid (PBA) has been shown to reduce ER stress is TSC-deficient cells. Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide arid glycerol may also be useful in treating tuberous sclerosis. The present invention provides methods of treating a subject suffering from tuberous sclerosis using ER stress reducers such as PBA, TUDCA, UDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in TSC-deficient cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating tuberous sclerosis. | 01-28-2010 |
20100022496 | GALENICAL FORM FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS BY TRANSMUCOUS MEANS - A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed. | 01-28-2010 |
20100022497 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject - A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the subject. | 01-28-2010 |
20100022498 | STEROIDS AS AGONISTS FOR FXR - The invention relates to compounds of formula (I): | 01-28-2010 |
20100029603 | 16ALPHA-METHYL OR ETHYL SUBSTITUTED ESTROGENS - The invention makes a 16α-substituted steroidal compound available having formula 1, | 02-04-2010 |
20100035855 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject - A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the subject. | 02-11-2010 |
20100048527 | Methods and compositions for the non-surgical removal of fat - Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction. | 02-25-2010 |
20100063018 | BILE ACID DERIVATIVES AS FXR LIGANDS FOR THE PREVENTION OR TREATMENT OF FXR-MEDIATED DISEASES OR CONDITIONS - The present invention relates to compounds of formula (I) | 03-11-2010 |
20100063019 | Low Dose Estrogen Interrupted Hormone Replacement Therapy - A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate. | 03-11-2010 |
20100075937 | Patient populations and treatment methods - The invention provides, inter alia, methods to treat, e.g., hyperglycemia or diabetes patients having two or more of a BMI of at least 28 or 29, a fasting insulin level of at least 4 μU/mL or at least 6 μU/mL and optionally (i) a serum MCP1 level of at least about 400 pg/mL or at least about 500 pg/mL. The treatment method includes administering 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol and optionally another compound such as metformin or glyburide. Specific embodiments include use of 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for the treatment of hypercholesterolemia in a patient and a BMI of at least 28 or 29 and optionally hyperglycemia. In these embodiments, the patient will most preferably have a fasting insulin level of at least 4 μU/mL or at least 5 μU/mL. | 03-25-2010 |
20100075938 | Use of Chemical Chelators as Reversal Agents for Drug-Induced Neuromuscular Block - The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having the general formula A | 03-25-2010 |
20100093687 | Method Of Treating Disorder Related To High Cholesterol Concentration - A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): | 04-15-2010 |
20100105645 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS - This invention relates to methods for using agents to inhibit peroxisome proliferator activated receptor expression. | 04-29-2010 |
20100105646 | ALLOPREGNANOLONE IN A METHOD FOR ENHANCING NEUROLOGICAL FUNCTION (ALZHEIMER DISEASE) - Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning. | 04-29-2010 |
20100130462 | LANOLIN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - A composition suitable for application to the skin comprising lanolin, an oil, an anti-oxidant, and a combination thereof. The composition is suitable for particular application to a human breast. | 05-27-2010 |
20100130463 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE - Disclosed are compounds of the formula: | 05-27-2010 |
20100152149 | Formulation - The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle. | 06-17-2010 |
20100152150 | THE APPLICATION OF MARINE STEROID IN PREPARING THE MEDICINE OF TREATING NEURONS DAMAGING - The application of marine steroid, i.e. 24-methylene-cholest-3β,5α,6β,19-tetrol, in preparing the medicine of treating neurons damaging is provided in the present invention. The keto-sterols compounds marine steroid YC-1 extracted from | 06-17-2010 |
20100152151 | TGR5 MODULATORS AND METHODS OF USE THEROF - The invention relates to compounds of Formula A: | 06-17-2010 |
20100160276 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 06-24-2010 |
20100173884 | USE OF A PHYTOSTEROL CONTAINING COMPOSITION FOR THE TREATMENT OF LUTS - The invention relates to the use of a composition comprising an oil-extract and a water-soluble extract, wherein said extracts are obtainable from plant materials and said extracts comprise phytosterols, for the manufacturing of a medicament for the treatment of females suffering from LUTS as a consequence of Interstitial Cystitis and/or stress or urge incontinence. | 07-08-2010 |
20100204191 | Function-Selective Vitamin D Receptor Agonist - The present invention provides a VDR ligand which does not induce hypercalcemia that is an adverse reaction of a vitamin D3 preparation; and a composition which comprises lithocholic acid propionate, a salt thereof, a solvate thereof, or a prodrug thereof. | 08-12-2010 |
20100204192 | AGENTS, COMPOSITIONS AND METHODS FOR ENHANCING NEUROLOGICAL FUNCTION - Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning. | 08-12-2010 |
20100222315 | Patient populations and treatment methods - The invention provides 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for use in methods to treat, e.g., hyperglycemia or diabetes patients having a body mass index of at least about 31 (≧30.5, ≧31 or ≧32), wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will generally have a fasting insulin level of at least 4 μU/mL or another characteristic as described herein. | 09-02-2010 |
20100227841 | Patient populations and treatment methods - The invention provides 17α-ethynylandrost-5-ene-3β,7β,17β-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will preferably have a fasting insulin level of at least 3.5 to 4 μU/mL. | 09-09-2010 |
20100240632 | DRUG FOR IMPROVING HYPERGLYCEMIA - A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia. | 09-23-2010 |
20100240633 | Cancer treatment methods - The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications. | 09-23-2010 |
20100249083 | 16,17-CARBOCYCLIC CONDENSED STEROID COMPOUNDS HAVING SELECTIVE ESTROGENIC ACTIVITY - The invention discloses a steroid compound having the formula (1): | 09-30-2010 |
20100261694 | Chemical chaperones and methods of use thereof for inhibiting proliferation of the phytopathogenic fungus Fusarium ssp. - Compositions and methods for preventing | 10-14-2010 |
20100273761 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS - The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided. | 10-28-2010 |
20100292201 | NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL - The present invention relates to steroidal esters of 17-oximino-5-androsten-3-ol, of compound of general formula (A) wherein R is selected from a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in comparison to Finasteride. Decreased androgen level have been found in serum of animal treated with newly synthesized compounds. These compounds have also shown better cytotoxicity in comparison to reference drug Finasteride. Thus such compounds can be useful in treatment of androgen dependent disorder of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferative activity. | 11-18-2010 |
20100311708 | USE OF NOR-BILE ACIDS IN THE TREATMENT OF ARTERIOSCLEROSIS - The present invention relates to the use of nor-bile acids and their pharmaceutically acceptable salts, esters and/or derivatives in the treatment arteriosclerosis. | 12-09-2010 |
20100317639 | Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids - A monoester of a family of steroids with a C | 12-16-2010 |
20100331292 | SUBSTITUTED 16,17-ANNELLATED STERIOD COMPOUNDS FOR USE IN WOMENS HEALTHCARE - The present invention relates to substituted steroid compounds having the formula | 12-30-2010 |
20110003782 | 23-Substituted Bile Acids as TGR5 Modulators and Methods of Use Thereof - The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation. | 01-06-2011 |
20110009375 | FUSIDIC ACID REGIMENS FOR TREATMENT OF BACTERIAL INFECTIONS - Novel dosing regimens for the treatment and prevention of bacterial infections using fusidic acid are described. The use of a high loading dose of fusidic acid, followed by moderate maintenance doses of the drug, have been found to prevent development of drug-resistant strains of bacteria, to increase the effective spectrum of the drug, and to avoid nausea and vomiting associated with a prolonged course of therapy of high amounts of the drug. | 01-13-2011 |
20110015167 | USE OF NORGESTIMATE AS A SELECTIVE INHIBITOR OF TRPC3, TRPC6 AND TRPC7 ION CHANNELS - TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention, norgestimate is shown to selectively inhibit TRPC3, TRPC6 and TRPC7. | 01-20-2011 |
20110046099 | STEROID HORMONE PRODUCTS AND METHODS FOR PREPARING THEM - The present invention relates to steroid hormone products, such as oral contraceptive products, including at least one steroid active ingredient mixed with an excipient and having improved dissolution and release rate properties. The invention further relates to methods for making such steroid hormone products, wherein a mixture of the hormone and the excipient is subjected to sufficient mechanical energy to form a powder blend wherein the hormone is stabilized by the excipient in substantially non-crystalline form. | 02-24-2011 |
20110086829 | COMPOSITIONS AND METHODS FOR TREATING OBESITY - Compositions and methods for treating obesity in a subject are described. Some embodiments provide methods for administering pharmaceutical formulations including biocompatible emulsifiers in an amount effective to treat obesity. In some embodiments, pharmaceutical formulations include a combination of two or more biocompatible emulsifiers effective to treat obesity. | 04-14-2011 |
20110092473 | ANDROSTANE AND PREGNANE STEROIDS WITH POTENT ALLOSTERIC GABA RECEPTOR CHLORIDE IONOPHORE MODULATING PROPERTIES - This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage. | 04-21-2011 |
20110098261 | TRITERPENOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS - The present invention relates to the use of triterpenoid-based compounds of formula (1) for inhibiting viral activity. The triterpenoid-based compounds have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases. | 04-28-2011 |
20110105451 | Screening of a Novel Hepatic Syndrome and its Uses - The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from a nucleic acid sample extracted from peripheral blood mononucleate cells, heterozygous mutations of the MDR3 gene and/or homozygous mutations of the MDR3 gene that do not eliminate the expression of the protein expressed by the MDR3 gene, which has phosphatidylcholine carrier activity, in adult subjects associating cholesterol biliary microlithiasis and intrahepatic cholestasis. | 05-05-2011 |
20110118228 | Enzymatic production or chemical synthesis and uses for 5,7-dienes and UVB conversion products thereof - Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds as shown in Tables 1 and 2. Also provided is a method for producing hydroxylated metabolites of cholecalciferol or ergocalciferol via the P450scc (CYP11A1) or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C20 of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. In addition, a method for inhibiting proliferation of either a normally or abnormally proliferating cell by contacting the cell with any of the compounds described herein. A related method is provided of treating a condition associated with the proliferating cell such as a cancer, a skin disorder, a defect in cell differentiation, cosmetic, prophylaxsis, or healthy cell maintenance. | 05-19-2011 |
20110136773 | Pharmaceutical Uses of Lanosta-8,24-dien-3-ols - The invention generally refers to pharmaceutical uses of lanosta-8,24-dien-3-ols, a family of tetracyclic terpenols, as anti-inflammatory, anticancerigenous and analgesic agents via the inhibition of the disordered activation of serine-threonine protein kinases, particularly PKC. | 06-09-2011 |
20110152229 | BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS - The present invention provides compounds of the general structure: | 06-23-2011 |
20110160173 | Method Of Treating Human Skin And A Skin Care Composition For Use In Such A Method - One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 μg/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R | 06-30-2011 |
20110160174 | Method Of Treating Disorder Related To High Cholesterol Concentration - A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): | 06-30-2011 |
20110172198 | TGR5 Modulators And Methods Of Use Thereof - The invention relates to compounds of Formula A: (A) or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease. | 07-14-2011 |
20110183949 | Use of Fulvestrant in the Treatment of Resistant Breast Cancer - The invention relates to the use of fulvestrant in the treatment of breast cancer in patients who have previously been treated with a Selective Estrogen Receptor Modulator (SERM) and an aromatase inhibitor. | 07-28-2011 |
20110183950 | TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH TUMOR PATHOLOGY RISK - The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of urogenital atrophy in women, said women having a high probability of developing an estrogen-dependent tumor or suffering or having suffered from an estrogen-dependent tumor. | 07-28-2011 |
20110190251 | METHOD FOR INHIBITING THE BUILD-UP OF ARTERIAL PLAQUE BY ADMINISTERING FULLERENES - Disclosed herein are methods of inhibiting the build-up of arterial plaque in a subject in need thereof. These methods comprise administering to the subject in need thereof a therapeutically effective amount of fullerenes. | 08-04-2011 |
20110195944 | MODIFIED RELEASE EMULSIONS FOR APPLICATION TO SKIN OR VAGINAL MUCOSA - Modified release oil in water emulsions that delivers drugs to a target tissue. The emulsions according to the present invention contain the lipophilic active ingredient completely dissolved into the hydrophobic internal phase stabilised by a polymeric surfactant. The presence of this polymer around the hydrophobic droplets avoids the migration of the active ingredient into the external hydrophilic phase and, consequently, its re-crystallization. | 08-11-2011 |
20110218181 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5. | 09-08-2011 |
20110224182 | SALTS OF (3-0-(3',3'-DIMETHYLSUCCINYL) BETULINIC ACID AND SOLID STATE FORMS THEREOF - The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, methods of making the compounds, polymorphic forms of the compounds, the compounds for use as medicaments, and use of the compounds for the manufacture of medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are certain salts of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid, also known as “DSB.” The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (“HIV”). | 09-15-2011 |
20110224183 | 16, 17-CARBOCYCLIC CONDENSED STEROID COMPOUNDS HAVING SLECTIVE ESTROGENIC ACTIVITY - The invention discloses a steroid compound having the formula (1): | 09-15-2011 |
20110257143 | Compositions and Method for the Treatment of Multiple Myeloma - The disclosure provides compositions and methods for treating multiple myeloma. In some embodiments, the compositions comprise (E)-3-hydroxy-21-[2′-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutical carrier. | 10-20-2011 |
20110257144 | NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE - The present invention relates to primary and secondary bacterial skin infections and in particular it relates to the treatment of these infections using a Fusidic acid cream that has been made using Sodium fusidate as the starting Active Pharmaceutical Ingredient (API). The invention discloses a dermaceutical cream containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. | 10-20-2011 |
20110263555 | TGR5 Modulators and Methods of Use Thereof - The invention relates to compounds of Formula (A): (A) or a salt, solvate, hydrate, or amino acid conjugate thereof. The compounds of formula A are TGR5 modulators useful for the prevention and treatment of disease. | 10-27-2011 |
20110275605 | Postprandial Hyperglycemia-Improving Agent - A postprandial hyperglycemia-improving agent, the agent is highly safe and exhibits excellent effects of inhibiting the postprandial increase of blood glucose. The postprandial hyperglycemia-improving agent comprises a cycloartenol or a derivative thereof as an active ingredient. | 11-10-2011 |
20110301137 | DERMACEUTICAL GEL MADE USING SODIUM FUSIDATE AND A PROCESS TO MAKE IT - The invention discloses a process to make dermaceutical gel containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment comprising an inert gas, preferably nitrogen. The gel produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The gel also contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, in a gel base; said gel base comprising a natural, semi-synthetic or synthetic polymers, a preservative, an acid, an alkali, a co-solvent, along with water, preferably purified water. The gel produced by the process of the present invention further optionally contains an ingredient selected from a group comprising, an anti oxidant, a chelating agent, and a humectant, or any combination thereof. | 12-08-2011 |
20110301138 | PROCESS TO MAKE FUSIDIC ACID CREAM - The invention discloses a process to make dermaceutical cream containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment created using inert gas, preferably nitrogen. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream produced by the process of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water. The cream produced by the process of the present invention further optionally contains an ingredient selected from a group comprising, a buffering agent, an anti oxidant, a chelating agent, and a humectant, or any combination thereof. | 12-08-2011 |
20110312929 | TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH CARDIOVASCULAR PATHOLOGY RISK - The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of urogenital atrophy in women said women having a high probability of suffering from a cardiovascular pathology or suffering or having suffered from a cardiovascular pathology. | 12-22-2011 |
20120022035 | Polymorphic and Amorphous Salt Forms of Squalamine Dilactate - The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation. | 01-26-2012 |
20120040946 | MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER AND A PROCESS TO MAKE IT - The present invention is directed to a medicinal composition for treating bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises a) a biopolymer in the form of Chitosan, b) an Active Pharmaceutical Ingredient (API), in the form of fusidic, c) a cream base, and d) water. The invention also discloses a process to make the medicinal cream in which Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, by converting it into Fusidic acid under oxygen-free environment created using inert gas, preferably nitrogen. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid and found to be surprisingly superior for use against skin infections with allergy & itching, & wounds on human skin than alternative creams currently available. | 02-16-2012 |
20120046265 | USE OF ERGOSTA-7,22-DIEN-3beta-OL IN THE TREATMENT OF CANCER - A use of an isolated and purified form of ergosta-7,22-dien-3β-ol in the treatment of cancer is provided. | 02-23-2012 |
20120071455 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS - Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ERβ agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives. | 03-22-2012 |
20120083481 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5. | 04-05-2012 |
20120108560 | SINGLE PHASE SILICONE ACRYLATE FORMULATION - This invention provides a single phase silicone acrylate formulation that resists phase separation and includes (A) at least one of a silicone, an acrylate, and combinations thereof. The single phase silicone acrylate formulation also includes (B) a silicone acrylate hybrid compatibilizing agent including silicone functionality and (meth)acrylate functionality and that is the reaction product of a silicon-containing pressure sensitive adhesive composition, a (meth)acrylate, and an initiator. A method of minimizing phase separation of the single phase silicone acrylate formulation includes the step of combining (A) and (B) to form the single phase silicone acrylate formulation. | 05-03-2012 |
20120108561 | STORAGE-STABLE, ANTI-MICROBIAL COMPOSITIONS INCLUDING CERAGENIN COMPOUNDS AND METHODS OF USE - Storage-stable, anti-microbial compositions and products include a carrier and a ceragenin compound suspended in the carrier. Ceragenin compounds suspended in the carrier include a sterol backbone and a number of cationic groups attached to the sterol backbone via hydrolysable linkages. The carrier has a pH of 5.5 or less, which acts to stabilize the hydrolysable linkages and increase the shelf-life of the anti-microbial compositions and anti-microbial products. Nevertheless, the ceragenin compounds described herein are designed to break down relatively quickly (e.g., within about 5 days) if the pH environment of the ceragenin compounds is raised to about pH 6.5 or greater. | 05-03-2012 |
20120115832 | TGR5 Modulators and Methods of Use Thereof - The invention relates to compounds of Formula A: | 05-10-2012 |
20120122830 | PREGNENOLONE SULFATE FOR THE TREATMENT OF NEUROLOGIC DISORDERS - The disclosure relates, in part, to methods of using pregnenolone sulfate (PREGS) to protect against the neurotoxicity of the β-amyloid peptide Aβ | 05-17-2012 |
20120142656 | BUCCAL APPLICATION SYSTEM COMPRISING 17A-ESTRADIOL - The invention relates to application systems for buccal application, comprising 17α-estradiol in a dosage of 50 to 400 μg, preferably 200 to 400 μg, particularly preferably 300 μg, together with one or more pharmaceutically acceptable additives or media for implementing the treatment or minimization of hot flashes in women having estrogen deficiencies. | 06-07-2012 |
20120142657 | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS - Compounds exhibiting 3alpha-hydroxy-5alpha/beta-steroid blocking action with no or only low antagonism against the gamma-aminobutyric acid (A) receptor (GABA-A), and compounds exhibiting partial antagonism against said receptor are presented. Methods for the prevention, treatment and/or alleviation of various CNS-disorders are suggested, as well as pharmaceutical compositions for such use. | 06-07-2012 |
20120157424 | TREATMENT OF MENOPAUSE-ASSOCIATED SYMPTOMS - Described are estradiol-containing pharmaceutical compositions and, and methods using the same to alleviate menopause-related symptoms, such as hot flushes, by topically administering estradiol at low effective doses. | 06-21-2012 |
20120178728 | USE OF A COPOLYMER IN THE FORM OF A SOLUBILISER FOR A POORLY WATER-SOLUBLE COMPOUND - The use of copolymers obtained by free-radical polymerization of a mixture of
| 07-12-2012 |
20120214778 | FULVESTRANT IN A DOSAGE OF 500mg FOR THE TREATMENT OF ADVANCED BREAST CANCER - The present disclosure is directed to fulvestrant at a dosage of 500 mg and its use in the treatment of a postmenopausal woman with advanced breast cancer. | 08-23-2012 |
20120214779 | APPLICATION OF 20(S)-PROTOPANAXADIOL IN PREPARATION OF ANTIDEPRESSANTS - The invention provides the novel use of 20(S)-protopanaxadiol in the preparation of medicaments for the treatment of depressive psychiatric disorders. The pharmacological test results indicated that the compound could remarkably increase the level of NE, 5-HT and HAV in the brains of model rats having depressive disorders, remarkably enhance tremors induced by 5-hydroxytryptophan (5-HTP) and behavioral effects induced by levodopa, and inhibit the re-uptake of 5-HT and NA. | 08-23-2012 |
20120220560 | STEROID TETROL SOLID STATE FORMS - The invention relates to solid state forms of androst-5-ene-3β,7β,16α,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes. | 08-30-2012 |
20120238537 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 09-20-2012 |
20120252774 | STEROID TETROL SOLID STATE FORMS - 2 - The invention relates to solid state forms of androst-5-ene-3α,7β,16β,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes. | 10-04-2012 |
20120258943 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5. | 10-11-2012 |
20120277203 | ANDROSTENEDIOL AS AN INDICATOR FOR ASSESSING ESTROGENICITY - The present invention provides methods of determining whether a female patient will benefit from hormone replacement therapy. | 11-01-2012 |
20120283234 | Bile Acid Derivatives As FXR Ligands For The Prevention Or Treatment Of FXR-Mediated Diseases Or Conditions - The present invention relates to compounds of formula (I): | 11-08-2012 |
20120302537 | TREATMENT METHODS USING PHARMACEUTICAL SOLID STATE FORMS - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 11-29-2012 |
20120309732 | METHOD FOR INHIBITION OF TUMOR CELL GROWTH USING (22R)-5alpha-LANOSTA-8,24-DIEN-3Beta,15alpha,21-TRIOL - In this patent, we isolated a novel compound from fruiting body of | 12-06-2012 |
20120322781 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES - It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addtion it is provided a method for preparing the pharmaceutical composition. | 12-20-2012 |
20120329766 | FORMULATION - The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle. | 12-27-2012 |
20130029958 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 01-31-2013 |
20130065871 | EMULSION COMPOSITION - An object of the present invention is to provide an emulsion composition that keeps smooth texture due to methyl polysiloxane, prevents the crystal precipitation of macadamia nut oil fatty acid phytosteryl to enhance formulation stability, and has a superior effect of conferring a resilient feel and emollient property. The present invention relates to an emulsion composition comprising (A) macadamia nut oil fatty acid phytosteryl, (B) methyl polysiloxane, and (C) one or more oils selected from the group consisting of glyceryl tri(2-ethylhexanoate), methylphenyl polysiloxane, cetyl ethylhexanoate, pentaerythrityl tetraethylhexanoate, and tripropylene glycol pivalate, wherein the content ratio of (A) to (C), (A):(C), is 1:3 to 1:200. | 03-14-2013 |
20130085125 | METHODS FOR THE SYNTHESIS AND PURIFICATION OF DEOXYCHOLIC ACID - Synthesis and purification of deoxycholic acid and its salts are provided. | 04-04-2013 |
20130102580 | COMPOSITIONS AND METHODS RELATED TO DEOXYCHOLIC ACID AND ITS POLYMORPHS - Provided herein are polymorphic forms of deoxycholic acid (DCA), improved methods of synthesizing DCA and intermediates thereto, and compositions and fat removal methods employing the DCA as provided herein. | 04-25-2013 |
20130102581 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract. | 04-25-2013 |
20130143854 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS - The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided. | 06-06-2013 |
20130150337 | SUBSTITUTED 16,17-ANNELLATED STEROID COMPOUNDS FOR USE IN WOMENS HEALTH - The present invention relates to substituted steroid compounds having the formula | 06-13-2013 |
20130157993 | USE OF 5ALPHA-ANDROSTANE (ALKYL)-3BETA,5,6BETA-TRIOL IN PREPARATION OF NEUROPROTECTIVE DRUGS - Disclosed is the use of 5α-androstane(alkyl)-3β,5,6β-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord isehemia or hypoxia and has no obvious toxic reaction within effective dose thereof. | 06-20-2013 |
20130172305 | Acute Treatment of Social Phobia - Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3β]-androsta-4,16-dien-3-ol. In some embodiments of the methods, both [3β}-androsta-4,16-dien-3-ol and [3α]-androsta-4,16-dien-3-ol are administered to a patient, and are included in a pharmaceutical composition for the treatment of social phobia. | 07-04-2013 |
20130172306 | USE OF AN ESTROGEN DERIVATIVE FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT AND/OR PREVENTION OF PSYCHIATRIC DISEASES AND FOR THE TREATMENT AND PREVENTION OF SAID DISEASES - The object of the invention is the use of 17-alpha-estradiol of formula (I) and its derivatives for the treatment and/or prevention of psychiatric clinical pictures. According to the invention, 17-alpha-estradiol and its derivatives can be used preferably as antidepressant drugs, especially preferably as quick-acting antidepressant drugs. According to the invention, 17-alpha-estradiol of formula (I) and its derivatives can also be used for the treatment and/or prevention of postpartum depression, post-menopausal depression, anxiety, schizophrenia, memory disturbance associated with depression or bipolar depression. | 07-04-2013 |
20130172307 | 5a-ANDROSTANE (ALKYL)-3b, 5, 6b-TRIOL INJECTION AND PREPARATION METHOD THEREFOR - A 5α-androstane-3β,5,6β-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-β-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-β-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-β-cyclodextrin solution, 5α-androstane-3β,5,6β-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection. | 07-04-2013 |
20130184246 | METHOD FOR TREATING FATTY LIVER DISEASES, IN PARTICULAR NON-ALCOHOLIC STEATOHEPATITIS - The invention is in the field of medical treatments of liver disease, in particular, non-alcoholic fatty liver diseases, such as non-alcoholic steatohepatitis. The invention provides a composition comprising an effective amount of a compound capable of increasing the intracellular level of 27-hydroxycholesterol for the treatment of liver inflammation in fatty liver disease. It also provides a method of reducing liver inflammation in a patient with non-alcoholic fatty liver disease by administering an effective amount of 27-hydroxycholesterol. | 07-18-2013 |
20130190280 | Anti-Diabetic Compounds - The preset invention relates to a new oral anti-diabetic compound prepared by synthesizing a steroid and a guanide or biguanide, which is eliminated via the hepatic route, instead of the renal route, to avoid adverse effects of Metformin, such as renal dysfunction. A pharmaceutical composition comprising the compound of the invention and the method for treating diabetes using the compound are also provided. | 07-25-2013 |
20130190281 | Compositions Containing Satiogens and Methods of Use - Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases. | 07-25-2013 |
20130190282 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5. | 07-25-2013 |
20130190283 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 07-25-2013 |
20130203722 | ESTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATIVE DISEASE AND DISORDERS - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period. | 08-08-2013 |
20130203723 | Preparation for Improving Solubility of Poorly Soluble Drug - The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B);
| 08-08-2013 |
20130210792 | METHOD OF TREATING DISORDER RELATED TO HIGH CHOLESTEROL CONCENTRATION - A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): | 08-15-2013 |
20130237508 | METHOD FOR PRODUCING y-ORYZANOL-CONTAINING FAT OR OIL - The disclosed method for producing a γ-oryzanol-containing fat or oil, the method comprising the steps of:
| 09-12-2013 |
20130244991 | USE OF 3-METHOXY-PREGNENOLONE FOR THE PREPARATION OF A DRUG FOR TREATING DEPRESSIVE DISORDERS AND LONG-TERM NEUROLOGICAL DISEASES - A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3∃-methoxy-pregna-5-ene-20-one (3∃-methoxy-PREG). | 09-19-2013 |
20130252931 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 09-26-2013 |
20130261096 | Formulation For Hormonotherapy - The present invention relates to a formulation as a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed phase, and comprising:
| 10-03-2013 |
20130261097 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM - A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition. | 10-03-2013 |
20130267489 | FULVESTRANT FORMULATIONS - Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C. | 10-10-2013 |
20130274236 | FULVESTRANT COMPOSITIONS AND METHODS OF USE - Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus crythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes. | 10-17-2013 |
20130281418 | Use of hydroxypregnenolone derivatives for enhancing health and physical performance - A method for the use of derivatives of hydroxypregnenolone (3-beta,17-alpha-dihydroxypregn-5-en-3-one) to enhance health and physical performance in humans and more particularly to the use of hydroxypregnenolone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and increasing cognitive function. | 10-24-2013 |
20130281419 | Therapeutic Uses for an Aminosterol Compound - A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. | 10-24-2013 |
20130281420 | Ophthalmic Formulations of Squalamine - The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium. | 10-24-2013 |
20130281421 | STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM AND METHODS FOR THEIR PRODUCTION - Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders. | 10-24-2013 |
20130281422 | Treatment of Pain Associated with Dislocation of Basal Endometrium - The present invention relates generally to gynecological diseases and in particular to a method for reducing pain associated with dislocation of basal endometrium. | 10-24-2013 |
20130345188 | Preparation and Uses of Obeticholic Acid - The present invention relates to obeticholic acid: | 12-26-2013 |
20140024630 | METHOD FOR THE NON-SURGICAL TREATMENT OF LIPODYSTROPHY IN A RETROVIRUS-INFECTED INDIVIDUAL - The present invention refers to a method for the non-surgical treatment of a lypodistrophy caused by an antiretroviral therapy in an individual infected by a retrovirus, such as HIV, and undergoing said antiretroviral therapy said method comprising the step of administering an effective amount of a adipocitolytic composition comprising deoxycholic acid and/or a pharmaceutically acceptable salt thereof in a retrovirus-infected individual affected by said lipodistrophy. | 01-23-2014 |
20140024631 | Steroids as Agonists for FXR - The invention relates to compounds of formula (I): | 01-23-2014 |
20140024632 | METHODS FOR TREATMENT OF AUTISM SPECTRUM DISORDER - The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorder. Accordingly, in one aspect, the present invention provides methods for treating patients with autism spectrum disorder. In one embodiment, a method for treating an autism spectrum disorder (ASD) in a patient comprises the step of administering a therapeutically effective amount of cholesterol to the patient. In more specific embodiments, the ASD is autism, Asperger's disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS), Rett's syndrome and childhood disintegrative disorder. In one embodiment, the patient has autism. | 01-23-2014 |
20140038932 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 02-06-2014 |
20140045807 | THE USE OF 3-METHOXY-PREGNENOLONE FOR THE PREPARATION OF A DRUG FOR TREATING A TRAUMATIC BRAIN INJURY - A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3β-methoxy-pregna-5-ene-20-one (3β-methoxy-PREG). | 02-13-2014 |
20140045808 | Reducing Risk of Contracting Clostridium-Difficile Associated Disease - A method of treating a patient to reduce risk of developing | 02-13-2014 |
20140057884 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER COMPRISING STIGMASTEROL AND 5 BETA-HYDROXYSITOSTANOL ISOLATED FROM NAVICULA INCERTA - A novel use of phytosterol isolated from | 02-27-2014 |
20140057885 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS - Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid. | 02-27-2014 |
20140057886 | Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions - The present invention relates to compounds of formula (I): | 02-27-2014 |
20140088059 | Compositions and Methods for Localized Drug Delivery through Mammary Papillae - The invention provides compositions and methods for the prevention, diagnosis, or treatment of conditions affecting breast tissue. The compositions can include one or more therapeutic agents or diagnostic agents, and an effective carrier. The composition can be specifically adapted for transdermal permeation through the mammary papilla, areola, or a combination thereof, and into underlying breast tissue. | 03-27-2014 |
20140088060 | METHOD OF TREATING DISORDER RELATED TO HIGH CHOLESTERAL CONCENTRATION - A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): | 03-27-2014 |
20140088061 | PHARMACEUTICAL COMPOSITION - The invention relates to a solid pharmaceutical composition comprising solid amorphous fulvestrant, said composition being formulated in combination with a solubilizing composition. The invention also relates to a method for preparing said composition and a kit including the composition. | 03-27-2014 |
20140088062 | COMPOSITIONS COMPRISING FUSIDIC ACID AND PACKAGES THEREFOR - Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases. | 03-27-2014 |
20140094443 | TGR5 Modulators and Methods of Use Thereof - The invention relates to compounds of Formula A: | 04-03-2014 |
20140100209 | TGR5 Modulators and Methods of Use Thereof - The invention relates to compounds of Formula A: | 04-10-2014 |
20140107090 | TREATMENT AND PREVENTION OF MASTITIS - Treating and Preventing mastitis employing cationic steroidal antimicrobials (CSAs). Treating or preventing clinical mastitis in a mammal includes administering a cationic steroidal anti-microbial compound (CSA) formulation to the intra-mammary organ of a mammal (e.g., a dairy cow), such as by injection into the mammary organ (e.g., through the teat of the mammary organ), and/or topical application. The dairy cow can be lactating and have a somatic cell count (SCC) less than or equal to 500,000 cells/mL at the time of administering the CSA formulation. Alternatively, the dairy cow can be lactating and have a somatic cell count (SCC) greater than 500,000 cells/mL at the time of administering the CSA formulation. The dairy cow can be taken out of production during the administration of the CSA formulation for a period of time of about 3 days or less, 2 days or less, or 1 day or less. | 04-17-2014 |
20140107091 | PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES - The present invention relates to a process for the preparation of a compound of formula (I) comprising the steps of a) reacting a compound of formula (II) with a silylating or an acylating agent to produce compound of formula (III), wherein P | 04-17-2014 |
20140148427 | NOVEL THERAPY FOR TREATMENT OF CHRONIC DEGENERATIVE BRAIN DISEASES AND NERVOUS SYSTEM INJURY - In one aspect, the present invention provides neuroactive steroids for use in the treatment of nervous system disorders, degenerative brain diseases and congenital storage diseases. In a second aspect, the invention provides neuroactive steroids in combination with a Liver X Receptor (LXR) ligand to effect treatment of a nervous system condition. | 05-29-2014 |
20140148428 | Treatment of Pulmonary Disease - The present invention relates to methods of treating, reducing the risk of preventing, or alleviating a symptom of a pulmonary disease or condition, reducing or suppressing inflammation in the lung, and promoting lung repair, by using a compound of formula A: | 05-29-2014 |
20140148429 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5. | 05-29-2014 |
20140155364 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5. | 06-05-2014 |
20140179656 | NEUROGENESIS SCREENING METHOD AND USES THEREOF - Provided herein are methods for detecting and/or confirming the neurogenesis effect of cholesterol and/or oxysterol utilizing adipose-derived stem cells (ADSCs). Further provided are methods of promoting neurogenesis in ADSCs. Also provided are methods for the use of cholesterol and/or oxysterol for the production of a neurologic component that may be incorporated into a nutritional composition for promoting neurogenesis in a pediatric subject. | 06-26-2014 |
20140179657 | METHOD FOR PRODUCING CAROTENOID COMPOSITION - The present invention provides an efficient method for industrially producing a naturally-derived carotenoid composition with a large amount of a carotenoid such as astaxanthin from a culture of a yeast of the genus | 06-26-2014 |
20140179658 | METHODS AND COMPOSITIONS FOR STIMULATION AND ENHANCEMENT OF REGENERATION OF TISSUES - Methods and pharmaceutical compositions are provided for enhancing or stimulating regeneration of a tissue in a subject. In one aspect, the invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an aminosterol or a pharmaceutically acceptable salt thereof to stimulate or enhance regeneration of a tissue. In another aspect, the invention provides a method including administering to a subject a therapeutically effective amount of an aminosterol or a pharmaceutically acceptable salt thereof to stimulate or enhance regeneration of a tissue to treat or prevent a disease, disorder, trauma, or condition resulting from an injury of the tissue. In an additional aspect, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of an aminosterol to stimulate or enhance regeneration of a tissue. | 06-26-2014 |
20140194401 | METHODS FOR REDUCING CELLULAR PROLIFERATION AND TREATING CERTAIN DISEASES - Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 07-10-2014 |
20140213565 | SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION - According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. | 07-31-2014 |
20140221329 | NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF - Novel mutant ESR1 molecules and uses are disclosed. | 08-07-2014 |
20140249125 | HIGH ENHANCER-LOADING POLYACRYLATE FORMULATION FOR TRANSDERMAL APPLICATIONS - A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives. | 09-04-2014 |
20140274987 | TRANSMUCOSAL HORMONE DELIVERY SYSTEM - The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the hormone estradiol, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition. | 09-18-2014 |
20140309204 | STEROID HORMONE PRODUCTS AND METHODS FOR PREPARING THEM - The present invention relates to steroid hormone products, such as oral contraceptive products, including at least one steroid active ingredient mixed with an excipient and having improved dissolution and release rate properties. The invention further relates to methods for making such steroid hormone products, wherein a mixture of the hormone and the excipient is subjected to sufficient mechanical energy to form a powder blend wherein the hormone is stabilized by the excipient in substantially non-crystalline form. | 10-16-2014 |
20140315873 | ANIMAL FEED INCLUDING CATIONIC CHOLESTEROL ADDITIVE AND RELATED METHODS - Methods and feed compositions for increasing health of agricultural animals include administering a cationic cholesterol additive through the diet of the animal, such as through solid feed or drinking water of the animals. The method includes feeding an animal a diet comprised of a cationic cholesterol additive, such as a compound with a sterol backbone and a plurality of cationic groups attached thereto. The feed composition may include a solid or liquid feed component and a cationic cholesterol additive. The methods and compositions are useful for animals raised in confined feed operations, such as cattle, swine, horses, sheep, or poultry, and can reduce harmful bacteria in the digestive tract, increase beneficial bacteria flora, improve feed conversion efficiency, reduce morbity and/or mortality, and/or yield harvested meat having reduced content of harmful bacteria. | 10-23-2014 |
20140315874 | 6-Substituted Demethyl-Estradiol Derivatives as Selective ER-Beta Agonists - Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ERβ agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives. | 10-23-2014 |
20140323455 | METHODS FOR PRESERVING PHOTORECEPTOR CELL VIABILITY FOLLOWING RETINAL DETACHMENT - Provided are methods for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a hydrophilic bile acid (e.g., UDCA or TUDCA) to a mammal having an eye with a detached retina. Administration of the hydrophilic bile acid maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid, thereby minimizing the loss of vision or visual acuity, which otherwise may occur as a result of the retinal detachment. | 10-30-2014 |
20140323456 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME - The present disclosure relates to esters of 8-[2-(2-pentyl-cyclopropylmethyl)cyclopropyl]-octanoic acid (“DCPLA”). The disclosure further relates to compositions, kits, and methods for treatment using the esters. | 10-30-2014 |
20140329790 | USE OF 5 alpha-ANDROSTANE-3 beta,5,6 beta-TRIOL IN PREPARATION OF NEUROPROTECTIVE DRUGS - Disclosed is the use of 5α-androstane-3β,5,6β-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof. | 11-06-2014 |
20140364405 | TREATMENT OF SEBORRHOEA - A method for the treatment of seborrhoea in a patient comprises administering to the patient an effective amount of (24RS) or (24S) scymnol, an ester thereof or a pharmaceutically acceptable salt of a said ester, or of (24R) scymnol. | 12-11-2014 |
20140371190 | Farnesoid X receptor modulators - The present invention provides a compound of formula (I): | 12-18-2014 |
20140371191 | Oromucosal Liquid Estradiol Compositions - The present invention relates to low dose estradiol solutions for oromucosal administration suitable in replacement therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with low endogenous levels of estradiol in female subjects. | 12-18-2014 |
20140378426 | Methods and compositions for enhancing visual function - The invention provides compositions of and methods for using estradiol and related compounds to improve visual function and to treat ocular degenerative disorders. | 12-25-2014 |
20150018326 | COMPOSITIONS AND METHODS FOR INHIBITING NOROVIRUS INFECTION - A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection. | 01-15-2015 |
20150018327 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS - Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders. | 01-15-2015 |
20150045335 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITONS AND METHODS - According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. | 02-12-2015 |
20150051182 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING - Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction. | 02-19-2015 |
20150072967 | TAUROURSODEOXYCHOLIC ACID ATTENTUATES OR ABOLISHES FORMATION AND DEPOSITION OF AMYLOID-B PEPTIDE - Methods of preventing or retarding or reversing or abolishing the onset and preventing the onset of neurodegenerative disease are discussed. This is achieved through the administration of a bile acid, a salt of the bile acid, an analog of the bile acid or any combinations of these compounds. The bile acid abolishes or interferes or down-regulates metabolic pathways leading to the onset of neurodegenerative diseases. The bile acid also activates metabolic pathways leading to the slowing or reversing or complete abolishment of the progression of neurodegenerative disease. | 03-12-2015 |
20150094292 | TOPICAL COMPOSITIONS CONTAINING NITRO FATTY ACIDS - Activated fatty acids, topical compositions including activated fatty acids and methods for using activated fatty acids to treat a variety of diseases. | 04-02-2015 |
20150105362 | SYNTHESIS OF ESTETROL VIA ESTRONE DERIVED STEROIDS - A process is provided for the making of estetrol starting from a 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is an C | 04-16-2015 |
20150133419 | ESTROGENIC COMPONENTS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol, in neurological disorders, such as neonatal hypoxic-ischemic encephalopathy (HIE). | 05-14-2015 |
20150133420 | BROAD ANTIVIRAL THERAPY WITH MEMBRANE MODIFYING OXYSTEROLS - This invention relates, e.g., to a method for inhibiting the growth and/or proliferation and/or infectivity of a virus in a cell, such as a mammalian cell (e.g. for inhibiting entry of the virus into the cell), comprising administering, or causing to be administered, to the cell, 25-hydroxycholesterol (25HC) in an amount sufficient to inhibit the growth and/or proliferation and/or infectivity of the virus in the cell. The method can be carried out in vivo or in vitro. Among the viruses that can be inhibited are, e.g., VSV, HSV, MHV68, HCV, HIV, EBOV, RVFV, RSSEV and Nipah virus. In one embodiment of the invention, the 25HC is administered topically, e.g. to a mucosal surface. | 05-14-2015 |
20150133421 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS - According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. | 05-14-2015 |
20150141390 | PLANT STEROIDS AND USES THEREOF - The invention relates to a drug conjugate including a drug and a plant steroid. The drug conjugate may target the drug for intestinal cell delivery, and thus may be used to treat diseases, including intestinal diseases, or to affect intestinal metabolism. The invention therefore also relates to treating intestinal diseases and affecting intestinal metabolism with the drug conjugate. | 05-21-2015 |
20150141391 | SYSTEMS AND METHODS FOR DETERMINING A TREATMENT COURSE OF ACTION - The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer. | 05-21-2015 |
20150313843 | SOLID GANAXOLONE COMPOSITIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 11-05-2015 |
20150313915 | ANTICONVULSANT ACTIVITY OF STEROIDS - The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone. | 11-05-2015 |
20150314342 | METHODS AND APPARATUS FOR CLEANING OR DISINFECTING A WATER DELIVERY SYSTEM - Methods for cleaning or disinfecting water delivery systems, self-cleaning or self-disinfecting water delivery systems, and inserts for use in cleaning or disinfecting water delivery systems utilize cationic steroidal antimicrobial (CSA) molecules to kill microbes and/or break up biofilms within water delivery systems. The methods and systems involve adding CSA molecules to water to form an aqueous CSA composition and passing the aqueous CSA composition through the water delivery system, such as a water storage vessel and/or water delivery line to clean or disinfect the water delivery system. CSA molecules can be added to a water storage vessel, water delivery line, or well, such as by a solid or liquid CSA composition. A CSA-eluting composition may provide CSA molecules to water to form an aqueous CSA composition that passes through or is stored within the water delivery system. CSA molecules provided to agricultural animals in drinking water may improve animal health. | 11-05-2015 |
20150315231 | New Steroids Having Increased Water Solubility and Resistance Against Metabolism and Methods For Their Production - Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders. | 11-05-2015 |
20150315627 | METHODS AND COMPOSITIONS FOR THE DETECTION OF FUNCTIONAL CLOSTRIDIUM DIFFICILE TOXINS - Methods and compositions for the identification of functional | 11-05-2015 |
20150320769 | Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Proliferation - Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S. | 11-12-2015 |
20150321993 | PHENOXY ALKYL DIETHANOLAMINE AND DIISOPROPANOLAMINE COMPOUNDS FOR DELIVERING ACTIVE AGENTS - The present invention relates to particular phenoxy alkyl diethanolamine and diisopropanolamine compounds for delivering biologically active agents to a target. These compounds are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other routes of administration to animals. | 11-12-2015 |
20150335650 | METHODS OF TREATING PR-POSITIVE, LUMINAL A BREAST CANCER WITH PI3K INHIBITOR, PICTILISIB - Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent. | 11-26-2015 |
20150342874 | Ophthalmic Formulations of Squalamine - The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium. | 12-03-2015 |
20150343066 | GEL COMPOSITIONS - The present invention provides a gel combination comprising: polycarbophil in an amount comprised from 1 to 5% by weight; polyvinylpirrolidone in an amount comprised from 4 to 8% by weight; glycerine in an amount comprised from 1 to 10% by weight; and propyleneglycolin an amount comprised from 20 to 40% by weight; wherein: the weight ratio between polyvinylpirrolidone:polycarbophil is comprised between 1:1 and 4:1, the weight ratio between glycerine:polycarbophil is comprised from 0.5:1 to 2:1, and the weight ratio propyleneglycol:polycarbophil is comprised from 8:1 to 20:1. The invention also provides transparent compositions comprising such gel combinations as well as processes for their preparation and the use thereof as a medicament. Due to the specific excipients, % by weight, and weight ratios forming the combination, the resulting compositions show a high bioadhesivity and bioavailability of the active ingredient, without toxic adverse effects. | 12-03-2015 |
20150359805 | Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions - The present invention relates to compounds of formula (I): | 12-17-2015 |
20150359806 | METHOD FOR PRODUCING PHYTOSTEROL/PHYTOSTANOL PHOSPHOLIPID ESTERS - The present invention relates to a method of producing a phytosterol ester and/or a phytostanol ester comprising: a) admixing a phospholipid composition comprising at least between about 10% to about 70% plant phospholipid and at least about 5% water; a lipid acyltransferase; and a phytosterol and/or a phytostanol; and b) separating or isolating or purifying at least one phytosterol ester and/or phytostanol ester from said admixture. The present invention also relates to compositions comprising the phytosterol ester and/or phytostanol ester produced by this method, including foodstuffs and personal care product (cosmetic) compositions. | 12-17-2015 |
20150368290 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME - This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from | 12-24-2015 |
20150374720 | METHODS AND PRODUCTS FOR INCREASING THE RATE OF HEALING OF TISSUE WOUNDS - Disclosed are methods for increasing the rate of healing of a tissue wound by administering a composition including a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting wound healing in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of a tissue wound. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 12-31-2015 |
20160000807 | COMPOUND AND METHOD FOR THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE CONDITIONS - A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5-en-26-oic (3β,7α-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention. | 01-07-2016 |
20160009753 | Reducing Risk of Contracting Clostridium-Difficile Associated Disease | 01-14-2016 |
20160022700 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 01-28-2016 |
20160022701 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF - Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and/or evaluating the sample for an alteration in the level S24(S)-hydroxycholesterol compared to a reference standard. | 01-28-2016 |
20160031930 | NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF - (3alpha,3beta)-disubstituted 17beta steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions. | 02-04-2016 |
20160039866 | 16- AND 17- DEUTERATED ESTROGEN-3-SULFAMATES AS ESTROGENIC AGENTS - The present invention relates to novel derivatives of estradiol, in particular to deuterated derivatives of estradiol sulfamates. The present invention also relates to compositions comprising said novel derivatives, as well as to uses of said novel derivatives and compositions comprising said derivatives. | 02-11-2016 |
20160045516 | Treatment Methods Using Pharmaceutical Solid State Forms - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 02-18-2016 |
20160051488 | HIGH ENHANCER-LOADING POLYACRYLATE FORMULATION FOR TRANSDERMAL APPLICATIONS - A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives. | 02-25-2016 |
20160051567 | PREVENTION AND TREATMENT OF KIDNEY DAMAGE - A method of treating or preventing kidney injury includes administering to a patient an effective amount of bile acid, a salt thereof, an analog thereof, or a combination thereof. Methods of preventing or retarding, reversing or abolishing the onset of kidney injuries are discussed. This is achieved through the administration of a bile acid, a salt of the bile acid, an analog of the bile acid or any combinations of these compounds. The bile acid abolishes or interferes or down-regulates metabolic pathways leading to the onset of kidney injury. The bile acid also activates metabolic pathways leading to the slowing or reversing or complete abolishment of the progression of acute kidney injury. | 02-25-2016 |
20160051684 | Natural Suspending Agent Including a Synergistic Blend of Xanthan Gum and Konjac Powder for Oral Pharmaceutical Suspensions - The present disclosure refers to a synergistic blend of Konjac powder and Xanthan gum that is included, as a natural suspending agent, in oral pharmaceutical suspensions. Oral pharmaceutical suspensions comprising the synergistic blend are aqueous solutions. The synergistic blend, used as a suspension agent to suspend suitable active pharmaceutical ingredients (APIs), improves the stability of oral pharmaceutical suspensions, and helps in the formation of a thermo-reversible gel and shear thinning necessary to keep APIs suspended within oral pharmaceutical suspensions. The synergistic blend of Konjac powder and Xanthan gum has unique anti-flocculation properties, which improve the homogeneity of the oral pharmaceutical suspensions. Additionally, the blend provides a better texture and mouth feel. Oral pharmaceutical suspensions, comprising the synergistic blend, include a vehicle, such as water, as well as different components, such as, for example APIs, preservatives, sweeteners, flavoring agents, and pH regulators or buffers, among others. | 02-25-2016 |
20160051685 | 5a-Androstane-3 ,5,6 -Triol Injection and Preparation Method Theref48 - A 5α-androstane-3β,5,6β-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-β-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-β-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-β-cyclodextrin solution, 5α-androstane-3β,5,6β-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection. Drying the filtrate yields a solid for injection. | 02-25-2016 |
20160052956 | TGR5 MODULATORS AND METHODS OF USE THEREOF - The invention relates to compounds of Formula A: | 02-25-2016 |
20160058773 | FULVESTRANT FORMULATIONS - Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed. | 03-03-2016 |
20160060288 | Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-tr- iene-3,17beta-diol having anticancer activity and preparation method thereof - The present invention provides a class of fulvestrant ester derivatives and preparation method thereof. Such a compound is an aliphatic ester formed by esterifying the —OH at positions C-3 and C-17 of fulvestrant, having a structure of the following formula: | 03-03-2016 |
20160068537 | COMPOUNDS FOR TREATMENT OF PAIN - The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. | 03-10-2016 |
20160074419 | Preparation and Uses of Obeticholic Acid - The present invention relates to obeticholic acid: | 03-17-2016 |
20160109472 | QUANTITATIVE MOLAR CONCENTRATION DETECTION OF SPECIFIC APOLIPOPROTEIN-CONTAINING PARTICLES PRESENT IN BODILY FLUIDS BY USING CAPILLARY ELECTROPHORESIS - A method for determining the molar concentration of specific lipoprotein particles present in a bodily fluid is presented. Multipixel Capillary Isotachophoresis Laser Induced Fluorescence is applied to fluorescently-labeled lipoproteins or immunologically-labeled apolipoproteins, facilitating quantification of lipoproteins and/or lipid particles and/or their associated apolipoproteins in a sample. The measurements are used to predict the risks of developing, progressing in severity of diseases related to lipoprotein particles, including cardiovascular and metabolic disorders. | 04-21-2016 |
20160120880 | BILE ACID-BASIC AMINO ACID CONJUGATES AND USES THEREOF - Compositions and methods for treating diseases or disorders associated with the metabolic syndrome using conjugates of bile acids with basic amino acids or a decarboxylated amino acid such as agmatine are provided. Further provided are bile acid-basic amino acid conjugates including chenodeoxycholic acid with an amino acid selected from arginine, lysine, histidine, ornithine or a decarboxylated amino acid such as agmatine. | 05-05-2016 |
20160129014 | FULVESTRANT FORMULATIONS - The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject. | 05-12-2016 |
20160137688 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyro-genic moieties. | 05-19-2016 |
20160151389 | USE OF ERGOSTATRIEN-3 -OL | 06-02-2016 |
20160165892 | PENTACYCLIC TRITERPENE COMPOUNDS AND USES THEREOF | 06-16-2016 |
20160166586 | METHOD FOR TREATING A DEGENERATIVE DISEASE OF THE NERVOUS SYSTEM USING 3-METHOXY-PREGNENOLONE OR DERIVATIVES THEREOF | 06-16-2016 |
20160175223 | ANTI-AGING COMPOSITIONS COMPRISING BILE ACID-FATTY ACID CONJUGATES | 06-23-2016 |
20160175322 | Treatment Methods Using Pharmaceutical Solid State Forms | 06-23-2016 |
20160175324 | ANTI-ACNE COMPOSITIONS COMPRISING BILE ACID-FATTY ACID CONJUGATES | 06-23-2016 |
20160184325 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS - The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α, 3α, 7α, 12α-tetrahydroxy-5β-cholanoic acid and 3α, 4α, 7α, 12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof. | 06-30-2016 |
20160193229 | COMPOSITIONS AND METHODS FOR INHIBITING NOROVIRUS INFECTION | 07-07-2016 |
20160193232 | TREATMENT AND PREVENTION OF MASTITIS | 07-07-2016 |
20160199390 | ANIMAL FEED INCLUDING CATIONIC CHOLESTEROL ADDITIVE AND RELATED METHODS | 07-14-2016 |
20170233431 | BILE ACID DERIVATIVES AND METHODS FOR SYNTHESIS AND USE | 08-17-2017 |
20170234881 | METHODS OF DIAGNOSING AND TREATING CANCER | 08-17-2017 |
20190142845 | ANTICONVULSANT ACTIVITY OF STEROIDS | 05-16-2019 |